Argus
•
Sep 02, 2026
ANIP: Lowering target price to $68.00
Summary
ANI Pharmaceuticals Inc develops, manufactures, and markets generic prescription pharmaceuticals. It manufactures liquid, powder, and oral solid-dose products.
Upgrade to begin using premium research reports and get so much more.
Exclusive reports, detailed company profiles, and best-in-class trade insights to take your portfolio to the next level
UpgradeRelated Reports
AMRX: What does Argus have to say about AMRX?
Sep 02, 2026
•
AMRX
PTCT: Lowering target price to $67.00
Sep 02, 2026
•
PTCT
COLL: Lowering target price to $23.00
Sep 02, 2026
•
COLL
AMPH: Raising target price to $24.00
Sep 02, 2026
•
AMPH
SUPN: Lowering target price to $42.00
Sep 02, 2026
•
SUPN
